Arvinas, Inc.
ARVN · NASDAQ
Market closed$8.01$-0.020000 (-0.25%)After hours $8.01 · 0.00%
Key statistics
Previous close$8.03
Open$7.94
Day high$8.18
Day low$7.90
52-week high$14.51
52-week low$6.06
Market cap516.81M
Volume494.56K
Average volume820.05K
P/E ratio-2.41
Forward P/E—
EPS-3.32
Dividend yield0.00%
Market context
Why it moved
ARVN shares edged slightly lower amid weak near-term market sentiment and no clear positive catalysts, with analyst commentary highlighting elevated downside risk and choppy trading conditions for the stock.
What is happening
Recent company-specific developments and publisher coverage.
The Globe and Mail · June 23, 2026Arvinas Announces Chief Medical Officer Leadership TransitionTradingView · June 5, 2026Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial DataStock Titan · June 4, 2026Arvinas joins Michael J. Fox effort to develop new Parkinson's therapiesReuters · May 12, 2026Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drugBioPharma Dive · May 12, 2026Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugGlobeNewswire · May 12, 2026Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate UpdateInvesting.com · May 12, 2026Arvinas stock gains after Rigel deal for VEPPANU rightsThe Clinical Trial Vanguard · May 5, 2026FDA Approves Arvinas’ Vepdegestrant for ESR1-Mutant Breast Cancer Mt Newswire · June 16, 2026Rigel Pharmaceuticals Closes Licensing Deal for Breast Cancer Drug Veppanu Benzinga · June 3, 2026Stephens & Co. Reiterates Overweight on Arvinas, Maintains $18 Price Target Benzinga · June 2, 2026Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028 Benzinga · June 1, 2026Full Transcript: Arvinas Q1 2026 Earnings Call Mt Newswire · May 14, 2026BofA Securities Raises Price Target on Arvinas to $16 From $14 Benzinga · May 13, 2026These Analysts Increase Their Forecasts On Arvinas After Q1 Results Benzinga · May 13, 2026Barclays Maintains Overweight on Arvinas, Raises Price Target to $20 Benzinga · May 13, 2026BTIG Maintains Buy on Arvinas, Raises Price Target to $18